TheBlackList Pub

For All Points-Of-The-View.

OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study - with findings related to younger women, African Americans and Hispanics

OncoSec Medical Incorporated ("OncoSec" or the "Company") (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced preliminary clinical observations related to its pilot biomarker OMS-I140 clinical trial of ImmunoPulse® IL-12 in patients with metastatic Triple Negative Breast Cancer (TNBC). The study is designed to assess whether a single cycle of ImmunoPulse IL-12 increases TNBC tumor immunogenicity by driving a pro-inflammatory cascade of events including activation of cytotoxic tumor-infiltrating lymphocytes (TILs).   

To date, five patients with TNBC have been treated with a single cycle of ImmunoPulse IL-12 (intratumoral pIL-12 [tavokinogene telseplasmid or "tavo"] with electroporation). Two of these five patients were subsequently treated with single agent nivolumab (Opdivo®) - an anti-PD-1 checkpoint inhibitor treatment - as their immediate next therapy. Both of these patients, who were heavily pretreated metastatic TNBC patients with chemotherapy refractory disease, experienced robust objective responses in both ImmunoPulse IL-12 treated and untreated lesions. These clinical observations have prompted the Company to further commit to a more definitive evaluation of the combined therapies.

"Metastatic TNBC is a heterogeneous cancer with a poor prognosis where less than five percent of pre-treated patients achieve an objective response to PD-1/PD-L1 checkpoint treatments," explained Sharron Gargosky, Chief Clinical and Regulatory Officer of OncoSec. "The marked synergy shown in these patients strongly suggests that IL-12 may have primed the tumor microenvironment, impacting the clinical result. The combination of ImmunoPulse IL-12 and checkpoint inhibition represents a highly promising new therapeutic approach for TNBC and warrants a formal evaluation given the extremely low response rate in women who have failed multiple prior therapies."

Previous studies have demonstrated that breast cancer patients whose tumors are associated with markers of inflammation, such as the presence of TILs, achieve better clinical outcomes. In addition, the density of TILs is a key requirement for the anti-tumor activity of immune checkpoint inhibitors like anti-PD-1/PD-L1 antibodies. By augmenting the expansion of CD8+ tumor infilatrating T cells, ImmunoPulse IL-12 may be an ideal candidate to combine with checkpoint inhibitors, which has demonstrated low and variable activity as a monotherapy in TNBC.

Immunological examination of samples from all patients are currently being analyzed. These data, along with the full information regarding clinical observations and safety data, will be submitted for presentation at an upcoming medical meeting in 2018.

To learn more about the trial, visit www.oncosec.com. Additional details can also be found atwww.clinicaltrials.gov via NCT02531425.

OPDIVO® is a registered trademark of Bristol-Myers Squibb Company.

ImmunoPulse® is a registered trademark of OncoSec Medical Incorporated, San Diego, CA, USA.

About Triple Negative Breast Cancer (TNBC)
Breast cancer cells that test negative for estrogen receptors (ER-), progesterone receptors (PR-), and HER2 (HER2-) means the cancer is triple negative.1 Approximately 15-20 percent of US breast cancer cases are triple negative breast cancer (TNBC),2 which disproportionately affects younger women as well as African-American women, followed by Hispanic women.3
CONTINUE FOR MORE

Views: 22


Donations Accepted

Discussion Forum

Shady Grove Fertility Study Examines Why African-American Women Experience Lower Pregnancy Rates Associated with In Vitro Fertilization as Compared with Caucasian Women

Started by Joyful Living Coaching Oct 26. 0 Replies

Shady Grove Fertility presented two new studies during the recent American Society for Reproductive Medicine’s 2018 Scientific Congress and Expo in Denver, CO that sought to better…Continue

Rev. Frederick Shaw: Rallying the NAACP to End Psychiatric Abuse of African American Children

Started by TheBlackList-Publisher Oct 25. 0 Replies

New documentary highlights one man's fight against multi-billion dollar psychiatric industry.In a new documentary in "The Voices for Humanity" series on the Scientology TV network, human rights advocate Rev. Frederick Shaw, Jr. takes on the…Continue

Howard University College of Medicine and the National Hispanic Council on Aging Introduce Urinary Incontinence Clinical Trials for Hispanic Women

Started by Bronx Scoop Oct 12. 0 Replies

 The Howard University College of Medicine and the National Hispanic Council on Aging (NHCOA), have partnered to introduce a pilot clinical trial program for older Hispanic Women with Urinary Incontinence. The study titled, "Multimodal Community…Continue

Videos

  • Add Videos
  • View All

© 2018   Created by KWASI Akyeampong.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Rivers APC Hails Rt. Hon. Chibuike Amaechi at 53
= = http://theblacklist.net/